News

New case of MS possibly related to tocilizumab


 

FROM MULTIPLE SCLEROSIS JOURNAL

References

Canadian researchers have reported the first case of a patient developing multiple sclerosis (MS) while taking tocilizumab for rheumatoid arthritis.

A 48-year-old woman with a 20-year history of rheumatoid arthritis was seen for right hemisensory symptoms that began as numbness and pain on her right foot that spread to her trunk, arm, and face over a week, Dr. Philippe Beauchemin and Dr. Robert Carruthers of the University of British Columbia, Vancouver, noted in Multiple Sclerosis Journal. She had received many treatments for rheumatoid arthritis, including hydroxychloroquine, etanercept, and adalimumab. She also was on methotrexate, vitamin D, naproxen, and dexlansoprazole. MRI showed 20 lesions consistent with the diagnosis of MS. Doctors immediately discontinued tocilizumab and methotrexate. Three months later, another MRI showed two new lesions confirming MS diagnosis.

designer491/Thinkstock

“There is absolutely no proof of a causal relationship between tocilizumab and MS in this patient, but it is also not excluded that tocilizumab might have caused secondary autoimmunity in CNS,” the authors wrote. The drug is in efficacy trials for patients with neuromyelitis optica spectrum disorder.

Two scenarios could explain this potential relationship, according to an accompanying commentary by Dr. Manuel Comabella of the Multiple Sclerosis Center of Catalonia, Vall d’Hebron University Hospital, Barcelona. The patient may have developed demyelinating lesions as a consequence of previous exposure to anti-TNF agents, and MS was later precipitated by treatment with tocilizumab; or that the drug itself can trigger a demyelinating disorder. “IL-6 may have immunosuppressive properties … that when absent by the effect of anti-IL6 agents, predisposes the individual to demyelinating conditions.”

Read the article in Multiple Sclerosis Journal (doi: 10:1177/1352458515623862).

Recommended Reading

All glucocorticoids linked to increased risk of VTE
MDedge Rheumatology
Medical marijuana: Tips from an expert
MDedge Rheumatology
Autoimmune disease coalition seeks to increase physician knowledge
MDedge Rheumatology
iPad app could change how MS is measured, treated
MDedge Rheumatology
Changing marijuana laws pose health challenges
MDedge Rheumatology
Specialty drug coupons - a double-edged sword of improved adherence, increased costs
MDedge Rheumatology
Specialty drugs: High cost, high value
MDedge Rheumatology
FDA issues new pregnancy/lactation drug label standards
MDedge Rheumatology
Rx for specialists: Know how ACA affects patients’ ability to pay for meds
MDedge Rheumatology
DMT may reduce disability-worsening events in multiple sclerosis
MDedge Rheumatology